ImmunoEdge
Contact
Unlocking immune targets from minimal tumor samples
ImmunoEdge is developing a technology to uncover clinically relevant immune peptides from routine core needle biopsies — unlocking the next generation of precision immunotherapy in cancer, inflammatory, and infectious diseases, from initial target discovery through patient selection and treatment response monitoring.
Get In Touch
ABOUT IMMUNOEDGE
Designed for clinical reality, ImmunoEdge is being built to uncover immune‑visible tumor peptides from ultra‑low‑input biopsies that standard workflows systematically miss, aiming to enable higher‑confidence and longitudinal immune target discovery for future immunotherapy programs.
THE CHALLENGE
Why traditional methods in immune target discovery don’t work
Current immunopeptidomics workflows can lose up to 99% of tumor immunopeptides from small biopsies, causing many clinically relevant immune targets to go undetected.
01
Loss and bias in affinity-based workflows
Affinity-based methods introduce sample loss and bias, especially with low-input tumor material, causing many immune-relevant peptides to be missed.
02
High sample requirements and single-shot analyses
Many workflows need large tumor samples and only allow single analyses, limiting longitudinal studies and real-world applicability.
03
Genome-based predictions miss low-expression targets
Predictive methods often overlook low-expression but immune-visible peptides, creating blind spots in discovery and therapeutic planning.
OUR SOLUTION
Unlocking precision for immunotherapy programs
Our approach is being built to overcome the limitations of standard workflows, empowering researchers and clinicians with actionable insights from small, real-world samples
Learn More
More complete and longitudinal visibility
Capture a broader landscape of immune targets over time, even from minimal biopsy samples, revealing dynamic changes that enable more informed therapeutic strategies.
Higher-confidence target selection
Prioritize immunotherapy candidates with confidence by relying on comprehensive, unbiased peptide data that reveals clinically relevant targets standard methods miss.
De-risked downstream therapeutic development
Reduce uncertainty in R&D programs by uncovering previously hidden tumor peptides, supporting better-informed decisions and more reliable translational outcomes.
OUR TEAM
Leadership behind ImmunoEdge
Mogjib Salek
PhD — Founder & CEO
Background in Structural Biochemistry and T-cell Signaling (Toulouse, Heidelberg, Oxford). Led neoepitope discovery across tumor types at DKFZ/NCT Heidelberg, revealing immunoprecipitation's limitations for clinical samples. Founded ImmunoEdge to develop purpose-designed technology that enables complete immune target profiling from routine core biopsies.
Jalal Vakili
MD, PhD — Executive Advisor
Clinical Oncology and Trial Strategy experience (Jules Bordet/Servier Oncology). Former CEO (Ovizio Imaging Systems & Chromacure SA) with a track record in partnerships, deal-making, and program leadership. Advising ImmunoEdge on strategy, partnerships, and business execution.
Our Advisory Board
Oreste Acuto, PhD
Pioneer in T-cell Receptor Signaling. Expertise in T-cell biology and immunotherapy translation (University of Oxford, Institut Pasteur, Dana-Farber Cancer Institute)
Christophe Masselon, PhD
Pioneer in Neutral Particle Mass Spectrometry. Expertise in clinical mass spectrometry and peptidomics systems (CEA, ETH Zürich, PNNL)
Daniel Böhi, PhD
Former CEO Capri-Sun. Executive Advisor for strategy, business development, and early-stage funding (Capri-Sun, Nestlé)
Join us in transforming cancer care
We are building collaborations with translational research teams across oncology, immunology, and infectious disease to advance precision immunotherapy development. If you're exploring next-generation immunopeptidomics for therapeutic or clinical applications and are interested in pilot or co‑development opportunities, we'd love to hear from you.
Become a Partner
FAQs
Frequently Asked Questions
Here are answers to some of the most frequently asked questions about ImmunoEdge, our approach.
What does ImmunoEdge do?
How is ImmunoEdge different from standard immunopeptidomics approaches?
What types of samples can ImmunoEdge work with?
How can I collaborate or learn more?
ImmunoEdge is currently exploring pilot collaborations with academic, biotech, and pharma teams on translational studies spanning oncology, inflammatory diseases, and infectious disease research. Whether you're developing next-generation immunotherapies, exploring patient stratification strategies, or studying immune responses to treatment, we'd love to discuss how we can work together. Contact info@immunoedge.de or connect via LinkedIn.
ImmunoEdge
Developing clinical‑grade immune target discovery from ultra‑low‑input samples.
Aiming to enable the next generation of precision immunotherapy.
ImmunoEdge is currently in pre‑commercial development and is not yet offering clinical or commercial services.
Supported by
© 2025 ImmunoEdge. All rights reserved.
Privacy Policy
ImmunoEdge
Contact
Unlocking immune targets from minimal tumor samples
ImmunoEdge is developing a technology to uncover clinically relevant immune peptides from routine core needle biopsies — unlocking the next generation of precision immunotherapy in cancer, inflammatory, and infectious diseases, from initial target discovery through patient selection and treatment response monitoring.
Get In Touch
ABOUT IMMUNOEDGE
Designed for clinical reality, ImmunoEdge is being built to uncover immune‑visible tumor peptides from ultra‑low‑input biopsies that standard workflows systematically miss, aiming to enable higher‑confidence and longitudinal immune target discovery for future immunotherapy programs.
THE CHALLENGE
Why traditional methods in immune target discovery don’t work
Current immunopeptidomics workflows can lose up to 99% of tumor immunopeptides from small biopsies, causing many clinically relevant immune targets to go undetected.
01
Loss and bias in affinity-based workflows
Affinity-based methods introduce sample loss and bias, especially with low-input tumor material, causing many immune-relevant peptides to be missed.
02
High sample requirements and single-shot analyses
Many workflows need large tumor samples and only allow single analyses, limiting longitudinal studies and real-world applicability.
03
Genome-based predictions miss low-expression targets
Predictive methods often overlook low-expression but immune-visible peptides, creating blind spots in discovery and therapeutic planning.
OUR SOLUTION
Unlocking precision for immunotherapy programs
Our approach is being built to overcome the limitations of standard workflows, empowering researchers and clinicians with actionable insights from small, real-world samples
Learn More
More complete and longitudinal visibility
Capture a broader landscape of immune targets over time, even from minimal biopsy samples, revealing dynamic changes that enable more informed therapeutic strategies.
Higher-confidence target selection
Prioritize immunotherapy candidates with confidence by relying on comprehensive, unbiased peptide data that reveals clinically relevant targets standard methods miss.
De-risked downstream therapeutic development
Reduce uncertainty in R&D programs by uncovering previously hidden tumor peptides, supporting better-informed decisions and more reliable translational outcomes.
OUR TEAM
Leadership behind ImmunoEdge
Mogjib Salek
PhD — Founder & CEO
Background in Structural Biochemistry and T-cell Signaling (Toulouse, Heidelberg, Oxford). Led neoepitope discovery across tumor types at DKFZ/NCT Heidelberg, revealing immunoprecipitation's limitations for clinical samples. Founded ImmunoEdge to develop purpose-designed technology that enables complete immune target profiling from routine core biopsies.
Jalal Vakili
MD, PhD — Executive Advisor
Clinical Oncology and Trial Strategy experience (Jules Bordet/Servier Oncology). Former CEO (Ovizio Imaging Systems & Chromacure SA) with a track record in partnerships, deal-making, and program leadership. Advising ImmunoEdge on strategy, partnerships, and business execution.
Our Advisory Board
Oreste Acuto, PhD
Pioneer in T-cell Receptor Signaling. Expertise in T-cell biology and immunotherapy translation (University of Oxford, Institut Pasteur, Dana-Farber Cancer Institute)
Christophe Masselon, PhD
Pioneer in Neutral Particle Mass Spectrometry. Expertise in clinical mass spectrometry and peptidomics systems (CEA, ETH Zürich, PNNL)
Daniel Böhi, PhD
Former CEO Capri-Sun. Executive Advisor for strategy, business development, and early-stage funding (Capri-Sun, Nestlé)
Join us in transforming cancer care
We are building collaborations with translational research teams across oncology, immunology, and infectious disease to advance precision immunotherapy development. If you're exploring next-generation immunopeptidomics for therapeutic or clinical applications and are interested in pilot or co‑development opportunities, we'd love to hear from you.
Become a Partner
FAQs
Frequently Asked Questions
Here are answers to some of the most frequently asked questions about ImmunoEdge, our approach.
What does ImmunoEdge do?
How is ImmunoEdge different from standard immunopeptidomics approaches?
What types of samples can ImmunoEdge work with?
How can I collaborate or learn more?
ImmunoEdge is currently exploring pilot collaborations with academic, biotech, and pharma teams on translational studies spanning oncology, inflammatory diseases, and infectious disease research. Whether you're developing next-generation immunotherapies, exploring patient stratification strategies, or studying immune responses to treatment, we'd love to discuss how we can work together. Contact info@immunoedge.de or connect via LinkedIn.
ImmunoEdge
Developing clinical‑grade immune target discovery from ultra‑low‑input samples.
Aiming to enable the next generation of precision immunotherapy.
ImmunoEdge is currently in pre‑commercial development and is not yet offering clinical or commercial services.
Supported by
© 2025 ImmunoEdge. All rights reserved.
Privacy Policy
Unlocking immune targets from minimal tumor samples
ImmunoEdge is developing a technology to uncover clinically relevant immune peptides from routine core needle biopsies — unlocking the next generation of precision immunotherapy in cancer, inflammatory, and infectious diseases, from initial target discovery through patient selection and treatment response monitoring.
Get In Touch
ABOUT IMMUNOEDGE
Designed for clinical reality, ImmunoEdge is being built to uncover immune‑visible tumor peptides from ultra‑low‑input biopsies that standard workflows systematically miss, aiming to enable higher‑confidence and longitudinal immune target discovery for future immunotherapy programs.
THE CHALLENGE
Why traditional methods in immune target discovery don’t work
Current immunopeptidomics workflows can lose up to 99% of tumor immunopeptides from small biopsies, causing many clinically relevant immune targets to go undetected.
01
Loss and bias in
affinity-based
workflows
Affinity-based methods introduce sample loss and bias, especially with low-input tumor material, causing many immune-relevant peptides to be missed.
02
High sample requirements and single-shot analyses
Many workflows need large tumor samples and only allow single analyses, limiting longitudinal studies and real-world applicability.
03
Genome-based predictions miss low-expression targets
Predictive methods often overlook low-expression but immune-visible peptides, creating blind spots in discovery and therapeutic planning.
OUR SOLUTION
Unlocking precision for immunotherapy programs
Our approach is being built to overcome the limitations of standard workflows, empowering researchers and clinicians with actionable insights from small, real-world samples
Learn More
More complete and longitudinal visibility
Capture a broader landscape of immune targets over time, even from minimal biopsy samples, revealing dynamic changes that enable more informed therapeutic strategies.
Higher-confidence target selection
Prioritize immunotherapy candidates with confidence by relying on comprehensive, unbiased peptide data that reveals clinically relevant targets standard methods miss.
De-risked downstream therapeutic development
Reduce uncertainty in R&D programs by uncovering previously hidden tumor peptides, supporting better-informed decisions and more reliable translational outcomes.
OUR TEAM
Leadership behind ImmunoEdge
Mogjib Salek
PhD — Founder & CEO
Background in Structural Biochemistry and T-cell Signaling (Toulouse, Heidelberg, Oxford). Led neoepitope discovery across tumor types at DKFZ/NCT Heidelberg, revealing immunoprecipitation's limitations for clinical samples. Founded ImmunoEdge to develop purpose-designed technology that enables complete immune target profiling from routine core biopsies.
Jalal Vakili
MD, PhD — Executive Advisor
Clinical Oncology and Trial Strategy experience (Jules Bordet/Servier Oncology). Former CEO (Ovizio Imaging Systems & Chromacure SA) with a track record in partnerships, deal-making, and program leadership. Advising ImmunoEdge on strategy, partnerships, and business execution.
Our Advisory Board
Oreste Acuto, PhD
Pioneer in T-cell Receptor Signaling. Expertise in T-cell biology and immunotherapy translation (University of Oxford, Institut Pasteur, Dana-Farber Cancer Institute)
Christophe Masselon, PhD
Pioneer in Neutral Particle Mass Spectrometry. Expertise in clinical mass spectrometry and peptidomics systems (CEA, ETH Zürich, PNNL)
Daniel Böhi, PhD
Former CEO Capri-Sun. Executive Advisor for strategy, business development, and early-stage funding (Capri-Sun, Nestlé)
Join us in transforming cancer care
We are building collaborations with translational research teams across oncology, immunology, and infectious disease to advance precision immunotherapy development. If you're exploring next-generation immunopeptidomics for therapeutic or clinical applications and are interested in pilot or co‑development opportunities, we'd love to hear from you.
Become a Partner
FAQs
Frequently Asked Questions
Here are answers to some of the most frequently asked questions about ImmunoEdge, our approach.
What does ImmunoEdge do?
How is ImmunoEdge different from standard immunopeptidomics approaches?
What types of samples can ImmunoEdge work with?
How can I collaborate or learn more?
ImmunoEdge is currently exploring pilot collaborations with academic, biotech, and pharma teams on translational studies spanning oncology, inflammatory diseases, and infectious disease research. Whether you're developing next-generation immunotherapies, exploring patient stratification strategies, or studying immune responses to treatment, we'd love to discuss how we can work together. Contact info@immunoedge.de or connect via LinkedIn.
ImmunoEdge
Developing clinical‑grade immune target discovery from ultra‑low‑input samples.
Aiming to enable the next generation of precision immunotherapy.
ImmunoEdge is currently in pre‑commercial development and is not yet offering clinical or commercial services.
Supported by
© 2025 ImmunoEdge. All rights reserved.
Privacy Policy